Lupin has reported results for fourth quarter and year ended March 31, 2014
The company has posted a rise of 328.58% in its net profit at Rs 571.17 crore for the quarter ended March 31, 2014 as compared to Rs 132.96 crore for the same quarter in the previous year. Total income of the company increased by 53.17% at Rs 2472.24 crore for quarter under review as compared to Rs 1613.99 crore for the quarter ended March 31, 2013.
On consolidated basis, the company has reported 35.51% rise in its net profit at Rs 553 crore for the quarter ended March 31, 2014 as compared to Rs 408.08 crore for the same quarter in the previous year. Total income of the company went up by 20.58% at Rs 3125.73 crore for quarter under review as compared to Rs 2592.04 crore for the quarter ended March 31, 2013.
For the year ended March 31, 2014, the company has posted a jump of 84.39% in its net profit at Rs 2324.22 crore as compared to Rs 1260.43 crore for the same period in the previous year. Total income of company has improved by 30.91% at Rs 9354.76 crore for year under review as compared to Rs 7145.82 crore for the period ended March 31, 2013.
For the year ended March 31, 2014, on the consolidated basis, the company has posted a rise of 39.73% in its net profit at Rs 1836.37 crore as compared to Rs 1314.16 crore for the same period in the previous year. Total income of company has increased by 17.93% at Rs 11403.05 crore for year under review as compared to Rs 9669.15 crore for the period ended March 31, 2013.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1869.30 |
| Dr. Reddys Labs. | 1358.95 |
| Cipla | 1475.70 |
| Zydus Lifesciences | 1121.55 |
| Lupin | 2410.50 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: